119 related articles for article (PubMed ID: 7695976)
1. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V; Yap A
Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
[TBL] [Abstract][Full Text] [Related]
2. Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer.
Chao TY; Hwang WS; Yang MJ; Chang JY; Wang CC; Hseuh EJ; Huang SH; Chen WC
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Oct; 56(4):232-8. PubMed ID: 8548664
[TBL] [Abstract][Full Text] [Related]
3. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
[TBL] [Abstract][Full Text] [Related]
4. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
5. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
[TBL] [Abstract][Full Text] [Related]
6. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
7. Combination of chemotherapy and recombinant interferon-alpha in advanced non-small cell lung cancer.
Hastürk S; Kurt B; Kocabaş A; Nadirler F; Orüc O
Cancer Lett; 1997 Jan; 112(1):17-22. PubMed ID: 9029165
[TBL] [Abstract][Full Text] [Related]
8. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
Kelly K; Crowley JJ; Bunn PA; Hazuka MB; Beasley K; Upchurch C; Weiss GR; Hicks WJ; Gandara DR; Rivkin S
J Clin Oncol; 1995 Dec; 13(12):2924-30. PubMed ID: 8523056
[TBL] [Abstract][Full Text] [Related]
9. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
Halme M; Maasilta PK; Pyrhönen SO; Mattson KV
Eur J Cancer; 1994; 30A(1):11-5. PubMed ID: 8142151
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
12. [An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Yoshimura A; Yamano Y; Gemma A; Yoshimori K; Hayashihara K; Taniguchi Y; Uematsu K; Shibuya M; Kudoh S; Niitani H
Gan To Kagaku Ryoho; 1993 Mar; 20(4):503-8. PubMed ID: 8383951
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer.
Rosell R; Carles J; Ariza A; Moreno I; Ribelles N; Solano V; Pellicer I; Barnadas A; Abad A
Cancer; 1991 May; 67(10):2448-53. PubMed ID: 1707745
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
16. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial.
Mandanas R; Einhorn LH; Wheeler B; Ansari R; Lutz T; Miller ME
Am J Clin Oncol; 1993 Dec; 16(6):519-21. PubMed ID: 8256769
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study.
Bowman A; Fergusson RJ; Allan SG; Stewart ME; Gregor A; Cornbleet MA; Greening AP; Crompton GK; Leonard RC; Smyth JF
Ann Oncol; 1990 Sep; 1(5):351-3. PubMed ID: 2175640
[TBL] [Abstract][Full Text] [Related]
20. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
Purohit A; Moreau L; Dietemann A; Seibert R; Pauli G; Wihlm JM; Quoix E
Lung Cancer; 1998 Nov; 22(2):119-25. PubMed ID: 10022219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
